 "Jubilant Life Sciences")
Shares of Jubilant Life Sciences have advanced nearly 2% to Rs 337 on the Bombay Stock Exchange (BSE) after the company revealed that it received US Food and Drug Administration’s (FDA) approval to market its drug- Zolmitriptan orally in the US market.
The drug is a generic version of Astra Zeneca that is used in treatment of migraine in adults.
In a filing to the BSE, the company announced that the tablets would be in strengths of 2.5mg and 5mg.
In a filing to the BSE, the company announced that the tablets would be in strengths of 2.5mg and 5mg.
As on June 30, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally.
The stock opened at Rs 334.90 and touched a high of Rs 344.80. A combined total of 1.27 million hands changed counter on the BSE and the NSE.
